CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Status Recruiting

Clinical Trial Summary

This study is a single-arm, open-label, dose-escalation clinical trial aimed at exploring the safety, tolerability, and pharmacokinetic characteristics of the CLL-1 CAR NK cells, as well as providing preliminary observations on its efficacy in subjects with relapsed/refractory acute myeloid leukemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06307054
Study type	Interventional
Source	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Recruiting
Phase	Phase 1
Start date	March 15, 2024
Completion date	March 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06141304` - Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT	Phase 2
Active, not recruiting	`NCT05029141` - New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Phase 2
Completed	`NCT03848754` - Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
Not yet recruiting	`NCT06007911` - Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT04722952` - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML	Phase 3
Withdrawn	`NCT03932318` - Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients	Phase 1/Phase 2
Recruiting	`NCT04310592` - Natural Killer Cell (CYNK-001) Infusions in Adults With AML	Phase 1
Recruiting	`NCT05237258` - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia	N/A
Active, not recruiting	`NCT04139434` - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML	Phase 1
Completed	`NCT05193448` - A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Recruiting	`NCT03867682` - Venetoclax and Lintuzumab-Ac225 in AML Patients	Phase 1/Phase 2
Recruiting	`NCT06022003` - Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT03091933` - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)	Phase 1/Phase 2
Active, not recruiting	`NCT04330820` - Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)	Phase 1/Phase 2
Recruiting	`NCT05305859` - Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML	Phase 2
Approved for marketing	`NCT03245424` - Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation